Taiwan adopts new approach to biotechnology-related invention applications
Managing IP is part of the Delinian Group, Delinian Limited, 4 Bouverie Street, London, EC4Y 8AX, Registered in England & Wales, Company number 00954730
Copyright © Delinian Limited and its affiliated companies 2024

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement
Sponsored content

Taiwan adopts new approach to biotechnology-related invention applications

Sponsored by

saint-island-400px.png
plant-tissue-culture-facility-2223464.jpg

Fiona Yin of Saint Island International Patent & Law Offices explains the ramifications of an announcement by the TIPO with regard to the implementation of WIPO Standard ST.26

In applying for biotechnology-related inventions, apart from submitting to the Taiwan Intellectual Property Office a copy of the specification with claims and necessary drawings, inter alia, the applicant should also pay attention to:

  • Whether the claimed invention involves a sequence of nucleotides or amino acids and hence a sequence listing needs to be filed; and

  • Whether it is necessary to make a domestic deposit of the involved biomaterials to meet the enabling requirement.

An announcement in July 2022 by TIPO relating to the above requirements is summarised as follows.

WIPO Standard ST.26 WIPO Standard ST.25 now only applies to any and all biotechnology-related invention applications filed before July 1 2022; i.e., it is only necessary to submit TIPO sequence listings in electronic TXT format for such cases. Following the adoption of a new standard by WIPO, starting from August 1 2022, sequence listings in XML files prepared in accordance with WIPO Standard ST.26, rather than the ST.25 standard, must be submitted with the relevant biotechnology-related invention applications in Taiwan.

Although nucleotide or amino acid sequences associated with biotechnogy-related inventions are mostly referred to in the Specifications, in order to facilitate exchange of sequence information and the necessary prior art searching and analysis, the applicant is required to prepare WIPO Standard sequence listings in XML files separately and attach the same to the electronic copy of the specification as part of the disclosure of the invention.

When a foreign applicant obtains the filing date of a patent application in the original language (for example, In English) and requests a belated submission of the Chinese version specification, Chinese version sequence listings prepared in accordance with WIPO Standard ST.26 need to be filed as well.

With regard to divisional applications, the applicant may choose to file sequence listings prepared in accordance with WIPO Standard ST.26 or sequence listings in TXT files, as is its parent application.

Viability statement

As Taiwan is not a member country of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure, the effect of a deposit made in an international depository under the treaty is generally not recognised in Taiwan. Hence, although certain biomaterials have been deposited in an international depository to meet the enabling requirement, the applicant is still required to make a corresponding deposit in a domestic depository designated by TIPO.

A domestic deposit can be exempted only when the international deposit was made in the UK, Japan, or South Korea, with which Taiwan has signed respective reciprocity agreements with regard to the depositing of biomaterials. In this respect, the certificates of deposit issued from the depository in the above three countries still need to be filed within four months from the filing date or 16 months from the earliest priority date claimed, whichever is applicable.

Furthermore, according to the announcement, a statement of viability must be indicated on the certificate of deposit. If a certificate of deposit does not contain a viability statement, or contains an unclear statement, the applicant shall be notified to submit a certificate of viability within the statutory period mentioned above. Otherwise, the biomaterials shall be deemed not deposited in the first place.

more from across site and ros bottom lb

More from across our site

AI
Tennessee has passed the ELVIS Act, a law that fights against AI models that mimic the voice and likeness of music artists
Rob Stien, chief communications and public policy officer at InterDigital, says the EU has forgotten innovators while trying to solve an issue that doesn’t exist
As Australia’s Qantm IP leans towards being acquired by a private equity company, sources discuss what it could mean for IP firms
Law firms that are conscious of their role in society are more likely to win work, according to a survey of over 23,000 in-house professionals
Nghiem Xuan Bac Pham, managing partner of Vision & Associates, discusses opportunities created by the US-China rift as well as profitability issues facing IP practices
Douglas Leite and two of his colleagues were intrigued by Bhering Advogados’s mission to grow its patent litigation practice
Each week Managing IP speaks to a different IP practitioner about their life and career
Counsel explain how pricing flexibility, patent agents and being business partners can help them maintain profitable patent prosecution practices
We provide a rundown of Managing IP’s news and analysis from the week, and review what’s been happening elsewhere in IP
Speakers at an INTA event weighed in on why firms should create AI use policies and how they stay on top of the latest developments
Gift this article